British Patient Capital announces $26.7m commitment to Kindred Capital’s third fund
Press release
British Patient Capital announces today a $26.7m commitment to Kindred Capital’s (“Kindred”) third fund as Kindred announces its close today at $130m.
Kindred adopts a high conviction investment strategy focused on mission-driven, founder-led technology companies at the early venture stage.
The investment follows a cornerstone commitment by British Patient Capital to the manager’s inaugural fund in 2017, as well as a further commitment to their second fund in 2020. Portfolio companies include Paddle, a UK-based specialist payments solutions provider for SaaS companies that reached unicorn status in 2022.
Kindred’s community-driven approach to partnering with entrepreneurs has proven appealing, helping attract quality opportunities. Through its Equitable Venture model, Kindred shares the profit of the fund with the founders in which the fund invests, encouraging its portfolio companies to actively help each other achieve their goals.
We are delighted to continue our relationship with Kindred with an investment in their third fund. Their investment approach of actively partnering with founders by building a network of collaboration within their portfolio is fully aligned with our mission to help innovative companies scale up and fulfil their potential.
Catherine Lewis La Torre CEO, British Patient Capital
We are truly grateful for the continued partnership of British Patient Capital, who have been there since day one with us as they had a cornerstone investment in our in inaugural fund. It’s true partners like this that enable us to keep supporting and fueling the innovate entrepreneurs that build companies in the UK. From fintech to fertility, cell and gene therapy to retirement communities, we see talented founders building businesses in many important spaces that help shape the future trajectory of the country.
Leila Zegna General Partner, Kindred Capital
Further Information
Quick links
Latest news
-
Read more about British Patient Capital announces $50.8m commitment to Evolution Technology Fund III Press release
25 April 2024 -
Read more about British Patient Capital announces £7m investment in Financial Wellbeing Fintech - Wagestream Press release
17 April 2024 -
Read more about British Patient Capital announces £5.5m commitment to Phagenesis Press release
04 March 2024